WO2006078811A3 - Preparations pharmaceutiques qui procedes d'utilisation - Google Patents

Preparations pharmaceutiques qui procedes d'utilisation Download PDF

Info

Publication number
WO2006078811A3
WO2006078811A3 PCT/US2006/001887 US2006001887W WO2006078811A3 WO 2006078811 A3 WO2006078811 A3 WO 2006078811A3 US 2006001887 W US2006001887 W US 2006001887W WO 2006078811 A3 WO2006078811 A3 WO 2006078811A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
release component
methods
component
formulations
Prior art date
Application number
PCT/US2006/001887
Other languages
English (en)
Other versions
WO2006078811A2 (fr
Inventor
Rodney A Brown
Stephen H Curry
Michael Rubenstein
Michael R Violante
Original Assignee
Pharmanova Inc
Quay Pharmaceuticals Ltd
Rodney A Brown
Stephen H Curry
Michael Rubenstein
Michael R Violante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36692870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006078811(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmanova Inc, Quay Pharmaceuticals Ltd, Rodney A Brown, Stephen H Curry, Michael Rubenstein, Michael R Violante filed Critical Pharmanova Inc
Priority to MX2007008833A priority Critical patent/MX2007008833A/es
Priority to EP06718892A priority patent/EP1838291A4/fr
Priority to AU2006206423A priority patent/AU2006206423A1/en
Priority to BRPI0614021-1A priority patent/BRPI0614021A2/pt
Priority to CA002595470A priority patent/CA2595470A1/fr
Priority to JP2007552260A priority patent/JP2008528494A/ja
Publication of WO2006078811A2 publication Critical patent/WO2006078811A2/fr
Publication of WO2006078811A3 publication Critical patent/WO2006078811A3/fr
Priority to IL184735A priority patent/IL184735A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouvelles préparations pharmaceutiques et de nouvelles utilisations médicales de gabapentine et de pregabaline. Ces préparations peuvent comprendre jusqu'à trois composants comprenant un composant à libération immédiate, un composant à libération soutenue et un composant à libération retardée. La proportion de chaque composant dans cette préparation peut-être réglée de façon à obtenir l'AUC souhaité et l'effet thérapeutique suivant l'administration à une personne par voie orale.
PCT/US2006/001887 2005-01-21 2006-01-20 Preparations pharmaceutiques qui procedes d'utilisation WO2006078811A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2007008833A MX2007008833A (es) 2005-01-21 2006-01-20 Formulaciones farmaceuticas y metodos de uso.
EP06718892A EP1838291A4 (fr) 2005-01-21 2006-01-20 Preparations pharmaceutiques qui procedes d'utilisation
AU2006206423A AU2006206423A1 (en) 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use
BRPI0614021-1A BRPI0614021A2 (pt) 2005-01-21 2006-01-20 formulações farmacêuticas e métodos de uso
CA002595470A CA2595470A1 (fr) 2005-01-21 2006-01-20 Preparations pharmaceutiques qui procedes d'utilisation
JP2007552260A JP2008528494A (ja) 2005-01-21 2006-01-20 医薬製剤および使用方法
IL184735A IL184735A0 (en) 2005-01-21 2007-07-19 Pharmaceutical formulations and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64585705P 2005-01-21 2005-01-21
US60/645,857 2005-01-21

Publications (2)

Publication Number Publication Date
WO2006078811A2 WO2006078811A2 (fr) 2006-07-27
WO2006078811A3 true WO2006078811A3 (fr) 2007-03-01

Family

ID=36692870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001887 WO2006078811A2 (fr) 2005-01-21 2006-01-20 Preparations pharmaceutiques qui procedes d'utilisation

Country Status (12)

Country Link
EP (1) EP1838291A4 (fr)
JP (1) JP2008528494A (fr)
KR (1) KR20070116588A (fr)
CN (1) CN101137352A (fr)
AR (1) AR062647A1 (fr)
AU (1) AU2006206423A1 (fr)
BR (1) BRPI0614021A2 (fr)
CA (1) CA2595470A1 (fr)
IL (1) IL184735A0 (fr)
MX (1) MX2007008833A (fr)
TW (1) TW200640497A (fr)
WO (1) WO2006078811A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
WO2009066325A1 (fr) 2007-11-23 2009-05-28 Lupin Limited Compositions pharmaceutiques de prégabaline à libération contrôlée
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EA039943B1 (ru) 2011-01-07 2022-03-30 Анджи Фарма (Юс) Элэлси Способ снижения уровней глюкозы в крови у субъекта
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
PT2704698T (pt) * 2011-05-05 2019-11-19 Hennig Arzneimittel Gmbh&Co Kg Forma farmacêutica para a libertação controlada de princípios activos
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
WO2013100873A1 (fr) * 2011-12-19 2013-07-04 Mahmut Bilgic Formulation pharmaceutique de prégabaline (taille de particules 300-2500 micromètres)
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
EP2800562A2 (fr) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions et procédés de traitement de troubles métaboliques
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
US20170273326A1 (en) * 2014-08-29 2017-09-28 Wakamoto Pharmaceutical Co., Ltd. Lactic acid bacteria-containing composition
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
EP3302425A4 (fr) * 2015-05-26 2018-12-26 Isa Odidi Prégabaline à libération prolongée contrôlée
RU2738114C2 (ru) * 2016-04-19 2020-12-08 Конарис Рисёрч Инститьют Аг Пероральные фармацевтические композиции никотинамида
BR112019000636A2 (pt) * 2016-07-17 2019-04-30 Mapi Pharma Ltd. formas de dosagem de liberação prolongada de pregabalina
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112023032B (zh) * 2020-09-14 2022-03-18 广东鼎信医药科技有限公司 一种含有消化酶的药物组合物及其制备方法
WO2022119430A1 (fr) 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Composition pharmaceutique solide recouverte et stable d'un analgésique et d'un antiépileptique contre la douleur
CN116898819B (zh) * 2023-06-09 2024-02-06 则正(上海)生物科技有限公司 一种普瑞巴林缓释剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906832A (en) * 1994-04-28 1999-05-25 Alza Corporation Method for treating epilepsies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7888298A (en) * 1997-01-03 1998-07-31 Elan Corporation, Plc Sustained release cisapride minitablet formulation
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
CN101410091A (zh) * 2002-01-04 2009-04-15 Ivax研究公司 用于持续释放格列吡嗪的药物递送系统
JP4625637B2 (ja) * 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
NZ556562A (en) * 2005-02-15 2010-08-27 Jazz Pharmaceuticals Inc Dosage form and method for sustained release of a substituted pyrazine compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906832A (en) * 1994-04-28 1999-05-25 Alza Corporation Method for treating epilepsies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOURASIA M.K. ET AL.: "Pharmaceutical approaches to colon targeted drug delivery systems", J. PHARM. PHARMACEUT. SCI., vol. 6, no. 1, 2003, pages 33 - 65, XP008078133 *
MAGNUS L.: "Nonepileptic Uses of Gabapentin", IPILEPSIA, vol. 40, no. SUPPL. 6, 1999, pages S66 - S72, XP000866519 *

Also Published As

Publication number Publication date
AR062647A1 (es) 2008-11-26
EP1838291A2 (fr) 2007-10-03
WO2006078811A2 (fr) 2006-07-27
BRPI0614021A2 (pt) 2011-03-01
IL184735A0 (en) 2007-12-03
MX2007008833A (es) 2008-03-25
EP1838291A4 (fr) 2008-12-03
TW200640497A (en) 2006-12-01
KR20070116588A (ko) 2007-12-10
JP2008528494A (ja) 2008-07-31
CA2595470A1 (fr) 2006-07-27
AU2006206423A1 (en) 2006-07-27
CN101137352A (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
WO2006078811A3 (fr) Preparations pharmaceutiques qui procedes d'utilisation
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
WO2007149406A3 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
WO2008061226A3 (fr) Formulations de topiramate à libération prolongée
WO2007092620A3 (fr) Formulations stables et leurs procedes de preparation et d'utilisation
WO2008027557A3 (fr) Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
WO2011146808A3 (fr) Formulation topique pour inhibiteur de jak
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2007092755A3 (fr) Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
IL178822A (en) Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2010070675A3 (fr) Formulation(s) topique(s) destinée(s) au traitement de l'inflammation, d'affections cutanées, de maladies des muqueuses et autres maladies associées à celles-ci
WO2008130803A3 (fr) Délivrance pulmonaire de microparticules d'insuline sphériques
WO2007012019A3 (fr) Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
MY173215A (en) Acetylcysteine compositions and methods of use thereof
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2010062581A3 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
CA2668320A1 (fr) Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
WO2009004995A1 (fr) Procédé de fixation et d'expression d'une substance physiologiquement active

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680006547.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006206423

Country of ref document: AU

Ref document number: 556566

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 184735

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2595470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008833

Country of ref document: MX

Ref document number: 12007501560

Country of ref document: PH

Ref document number: 2007552260

Country of ref document: JP

Ref document number: 2006718892

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5666/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006206423

Country of ref document: AU

Date of ref document: 20060120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077019105

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0614021

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20070723